Submit Your Feeds

Business News • PR NewsWire • Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)

Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)

THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral

View More : http://www.prnewswire.com/news-releases/amgen-and-ucb-announce-positive-phase-2-results-of-amg-785cdp7851-in-patients-wi...
Releted News by prnewswire
Publicis Groupe - 1st Quarter 2011 Revenue
Regional Energy Supply Challenges to be Addressed at Power Morocco
Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2017
Reportlinker Adds Frontiers in Carbohydrates Developments: Report 1; Research, Technologies - Selected Starch Derivatives and Hydrocolloids, January 2011
Home Sitemap Contact Us
© businessNewsNewsNews.com